Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Abstract

For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response. However, mutational status at baseline may influence response. Less sensitive mutations that occurred at three residues defined in this study, as well as the T315I mutation, may be associated with less favorable responses to nilotinib.